RxDoctor Payments Data

Steven Goldenberg, OD

Optometrist · Johnson City, NYNPI 1689621955

Payments from drug & device makers

$2,464in general payments, 2019–2025

Across 102 payments — averaging $24.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Quidel Corporation$493
  • Alcon$343
  • Novartis$269
  • AbbVie$259
  • Oyster Point Pharma, Inc.$227
  • Bausch & Lomb Americas Inc.$158
  • plus $715 from 12 others

What the payments were for

  • Travel & lodging$49320%
  • Food & beverage$1,83274%
  • Education$1406%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,464 in reported general payments places this provider in the 80th percentile of 2,743 optometrist providers in New York.

See all optometrist providers in New York

Medicare billing

Part B allowed, 2024
$89,188
Medicare patients
626
Services billed
918

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine36$61,282
XiidraLifitegrast34$54,463
LumiganBimatoprost62$36,709
Cyclosporine32$23,514
MieboPerfluorohexyloctane/Pf16$16,176
Travoprost33$7,762
CombiganBrimonidine Tartrate/Timolol17$7,418
Latanoprost331$5,439
Timolol Maleate192$5,195
SimbrinzaBrinzolamide/Brimonidine Tart27$5,157
Brinzolamide11$3,089
Brimonidine Tartrate29$2,154
Prednisolone Acetate42$1,877
Fluorometholone14$1,369
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat66$1,284

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Combigan$259$105,409115 claims
Bausch & Lomb Americas Inc.Xiidra, Miebo$158$70,63950 claims
AlconSimbrinza$343$5,15727 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,743 optometrist providers in New York.

Other optometrist in Johnson City

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →